Eddine Saiah

Eddine Saiah is the current Chief Scientific Officer at Stablix. Prior to this, they were with Navitor Pharmaceuticals from October 2014 to December 2022 where they were promoted several times to ultimately Chief Scientific Officer. Eddine was responsible for all research activities including target selection and validation, pharmacology, medicinal chemistry, PK, tox and biomarker strategy through IND filing and early clinical development (phase Ib proof of concept). Saiah successfully built a multidisciplinary team and advanced a robust platform of novel targets in the mTORC1 pathway including activators and inhibitors as modulators of autophagy and lysosomal function with indications in rare disease, CNS, immuno-oncology and fibrosis. Eddine completed several IND filings with lead program in phase 2 clinical trials. Saiah also established multiple collaborations with academic institutions and CROs to support and complement internal resources. Eddine took an active role in financing and BD activities: actively networked with investors and partners, delivered key research milestones, which contributed to the trigger of various tranches and the continuous funding of the company.

Before their time at Navitor Pharmaceuticals, Saiah was Entrepreneur in Residence at Atlas Venture from June 2013 to September 2014.

Eddine Saiah completed their Ph.D. in Chemistry at Pierre and Marie Curie University.